Molecular diagnosis and genomics have opend a window for a better outcome especially in children with hematologic malignancies and most of all in pediatric BCP-ALL which has a cure rate of almost 90% but there is still some grey zone that has tobe cleared up in this innocent looking and most common hematologic malignancy